Lister R G, Greenblatt D J, File S E
Psychopharmacology (Berl). 1984;84(3):420-2. doi: 10.1007/BF00555224.
A rapid and sensitive method is described for the determination of CGS-8216 (a pyrazoloquinoline that displaces benzodiazepines from their binding sites in the brain but which reverses some of the behavioural actions of the benzodiazepines) in plasma using high-performance liquid chromatography with ultraviolet detection. CGS-9896 serves as the internal standard. The method is applied to a pharmacokinetic study of CGS-8216 in the rat. CGS-8216 was not detectable in plasma 24 h after a single IP administration of a 10 mg/kg dose. Animals treated with five once-daily injections of CGS-8216 had plasma concentrations 30 min after the final injection that were approximately four-times those observed 30 min after a single treatment. This suggests that caution must be used in the interpretation of results from experiments using multiple administrations of CGS-8216. The compound could not be detected in brain tissue at any of the time points studied.
描述了一种快速灵敏的方法,用于使用带紫外检测的高效液相色谱法测定血浆中的CGS-8216(一种吡唑并喹啉,可将苯二氮䓬从其在脑中的结合位点置换出来,但能逆转苯二氮䓬的一些行为作用)。CGS-9896用作内标。该方法应用于大鼠体内CGS-8216的药代动力学研究。单次腹腔注射10mg/kg剂量的CGS-8216后24小时,血浆中未检测到CGS-8216。用CGS-8216每日一次注射五次的动物,在最后一次注射后30分钟的血浆浓度约为单次给药后30分钟观察到的浓度的四倍。这表明在解释使用多次给药的CGS-8216的实验结果时必须谨慎。在所研究的任何时间点,脑组织中均未检测到该化合物。